These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22778844)

  • 1. (S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for Major Depressive Disorder (MDD).
    Lindsley CW
    ACS Chem Neurosci; 2010 Aug; 1(8):530-1. PubMed ID: 22778844
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant.
    Vieta E; Thase ME; Naber D; D'Souza B; Rancans E; Lepola U; Olausson B; Szamosi J; Wilson E; Hosford D; Dunbar G; Tummala R; Eriksson H
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):564-74. PubMed ID: 24507016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine.
    Shytle RD; Silver AA; Sheehan KH; Sheehan DV; Sanberg PR
    Depress Anxiety; 2002; 16(3):89-92. PubMed ID: 12415531
    [No Abstract]   [Full Text] [Related]  

  • 4. Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy.
    Möller HJ; Demyttenaere K; Olausson B; Szamosi J; Wilson E; Hosford D; Dunbar G; Tummala R; Eriksson H
    World J Biol Psychiatry; 2015 Oct; 16(7):483-501. PubMed ID: 25602163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of dexmecamylamine (TC-5214) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to antidepressant therapy: results of a long-term study.
    Tummala R; Desai D; Szamosi J; Wilson E; Hosford D; Dunbar G; Eriksson H
    J Clin Psychopharmacol; 2015 Feb; 35(1):77-81. PubMed ID: 25514064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study.
    George TP; Sacco KA; Vessicchio JC; Weinberger AH; Shytle RD
    J Clin Psychopharmacol; 2008 Jun; 28(3):340-4. PubMed ID: 18480694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests.
    Andreasen JT; Redrobe JP
    Behav Brain Res; 2009 Jan; 197(1):150-6. PubMed ID: 18786574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar activity of mecamylamine stereoisomers in vitro and in vivo.
    Papke RL; Stokes C; Muldoon P; Imad Damaj M
    Eur J Pharmacol; 2013 Nov; 720(1-3):264-75. PubMed ID: 24161916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mecamylamine (Targacept).
    Singh A; Das DK; Kelley ME
    IDrugs; 2006 Mar; 9(3):205-17. PubMed ID: 16523387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotinic acetylcholine receptors as targets for antidepressants.
    Shytle RD; Silver AA; Lukas RJ; Newman MB; Sheehan DV; Sanberg PR
    Mol Psychiatry; 2002; 7(6):525-35. PubMed ID: 12140772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.
    Lyoo IK; Yoon S; Kim TS; Hwang J; Kim JE; Won W; Bae S; Renshaw PF
    Am J Psychiatry; 2012 Sep; 169(9):937-945. PubMed ID: 22864465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [SSRI enantiomers already effective after 8 days. The proper twist against depression].
    MMW Fortschr Med; 2003 Nov; 145(47):60. PubMed ID: 14725038
    [No Abstract]   [Full Text] [Related]  

  • 13. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity.
    Lippiello PM; Beaver JS; Gatto GJ; James JW; Jordan KG; Traina VM; Xie J; Bencherif M
    CNS Neurosci Ther; 2008; 14(4):266-77. PubMed ID: 19040552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Star-D: lessons learned and future implications.
    Rush AJ
    Depress Anxiety; 2011 Jul; 28(7):521-4. PubMed ID: 21721070
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential therapeutic uses of mecamylamine and its stereoisomers.
    Nickell JR; Grinevich VP; Siripurapu KB; Smith AM; Dwoskin LP
    Pharmacol Biochem Behav; 2013 Jul; 108():28-43. PubMed ID: 23603417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
    Lam RW; Lönn SL; Despiégel N
    Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes.
    Papke RL; Sanberg PR; Shytle RD
    J Pharmacol Exp Ther; 2001 May; 297(2):646-56. PubMed ID: 11303054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term intravenous citalopram augmentation in partial/nonresponders with major depression: a randomized placebo-controlled study.
    Altamura AC; Dell'Osso B; Buoli M; Bosi M; Mundo E
    Int Clin Psychopharmacol; 2008 Jul; 23(4):198-202. PubMed ID: 18545057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram.
    Popik P; Kozela E; Krawczyk M
    Br J Pharmacol; 2003 Jul; 139(6):1196-202. PubMed ID: 12871839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.
    Bruno A; Morabito P; Spina E; Muscatello MR
    Curr Neuropharmacol; 2016; 14(2):191-9. PubMed ID: 26572745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.